Acadia Pharmaceuticals Faces EU Setback for Rett Syndrome Drug Trofinetide

Acadia Pharmaceuticals (ACAD) receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request.